Early modulation of pituitary gonadotropins during PD-1 inhibitor–based immunochemotherapy in patients with solid tumors
This longitudinal study reveals that PD-1 inhibitor-based immunochemotherapy in patients with lung and colorectal cancer induces selective, progressive alterations in pituitary hormones (specifically increasing FSH and prolactin while decreasing the LH/FSH ratio) without causing significant changes in circulating gonadal sex steroids, suggesting a primary pituitary-level endocrine response rather than overt gonadal dysfunction.